Table 1.
Characteristics of the study population
| Characteristic | Patients with AD (N = 77,682) |
|---|---|
| Demographic and clinical variables | |
| Age at the onset of the pandemic, years | |
| Mean (SD) | 41.9 (18.6) |
| Median (range) | 37.2 (18.2–112.3) |
| Sex, n (%) | |
| Male | 29,873 (38.5) |
| Female | 47,809 (61.5) |
| Ethnicity, n (%) | |
| Jews | 65,969 (84.9) |
| Arabs | 11,713 (15.1) |
| Socioeconomic status, n (%) | |
| Low | 25,019 (32.2) |
| Intermediate | 32,255 (41.5) |
| High | 20,408 (26.3) |
| BMI, mean (SD), mg/kg2 | 25.4 (5.3) |
| Characteristics of AD | |
| Age at the onset of AD, years | |
| Mean (SD) | 34.2 (19.7) |
| Median (range) | 30.5 (0.3–101.2) |
| Adult-onset AD, n (%)a | 59,638 (76.8) |
| Severity of AD, n (%)b | |
| Mild | 71,986 (92.7) |
| Moderate to severe | 5696 (7.3) |
| Treatment modalities during the pandemic | |
| Immunosuppressive agents, n (%)c | 597 (0.8) |
| Azathioprine | 127 (0.2) |
| Mycophenolate mofetil | 71 (0.1) |
| Methotrexate | 71 (0.1) |
| Cyclosporine | 92 (0.1) |
| Dupilumab | 236 (0.3) |
| Phototherapy, n (%)d | 472 (0.6%) |
| Treatment modalities anytime during the course of the diseases | |
| Immunosuppressive agents, n (%)c | 1038 (1.3) |
| Phototherapy, n (%)d | 2163 (2.8) |
AD atopic dermatitis, BMI body mass index, SD standard deviation
aDefined when the onset of AD follows the age of 18 years
bModerate-to-severe cases of AD were defined in those who were managed by systemic drugs and/or phototherapeutic modalities anytime during the course of AD
cAzathioprine, mycophenolate mofetil, methotrexate, cyclosporine, dupilumab
dUltraviolet B or psoralen and ultraviolet A